Full Press Release Details
regeneron and alnylam report positive interim phase 1 clinical data on aln app an investigational rnai therapeutic for alzheimer s disease and cerebral amyloid angiopathy.
REGN
regeneron and alnylam report positive interim phase 1 clinical data on aln app an investigational rnai therapeutic for alzheimer s disease and cerebral amyloid angiopathy
Key Takeaway: regeneron and alnylam report positive interim phase 1 clinical data on aln app an investigational rnai therapeutic for alzheimer s disease and cerebral amyloid angiopathy